Medline: 2745195

International Journal of Radiation Oncology, Biology, Physics 17(1): 21-27, 1989.

The predictive value of progesterone receptor levels in endometrial cancer.

Ingram SS, Rosenman J, Heath R, et al.


Recent reports have suggested that the presence of progesterone receptor correlates with other well-known predictors of a favorable outcome for endometrial cancer patients. To test this hypothesis, we reviewed the records of 154 patients who had undergone a hysterectomy for adenocarcinoma of the endometrium, and pelvic irradiation if poor prognostic factors were present. The 3-year disease-free survival for all clinical Stage I patients was 80%. Patients with progesterone receptor levels greater than or equal to 100 had a 3-year disease-free survival of 93% compared with only a 36% 3-year disease-free survival for patients with progesterone receptor less than 100 (p less than .0001, log rank test). To determine whether elevated progesterone receptor was an independent prognostic factor for disease-free survival in endometrial cancer, or just correlated with the other well-known predictors, bivariate and multivariate analyses were conducted. Our results indicate that progesterone receptor levels are the single most important prognostic indicator of 3-year disease-free survival in clinical Stage I endometrial cancer, with only cervical involvement and peritoneal cytology being significant prognostic variables after adjusting for progesterone receptor levels.

This is a service of:

Uni Logo

Rheinische Friedrich- Wilhelms- Universität Bonn
Medical Center

Dr. G. Quade